Elevation Oncology Inc Quick Ratio (ELEV) starting from the first quarter 2025 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Elevation Oncology inc   (NASDAQ: ELEV)

Elevation Oncology Inc 's Quick Ratio

ELEV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2025, Quick Ratio deteriorated to 19.04 above company average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Quick Ratio than Elevation Oncology Inc in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 61 to 213.

Explain Quick Ratio?
How much Cash & cash equivalents ELEV´s has?
What are ELEV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ELEV Quick Ratio (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1
Y / Y Current Liabilities Change 81.49 % 7.77 % -22.1 % -67.17 % -82.75 %
Y / Y Cash & cash equivalent Change -22.48 % 12.13 % 8.73 % 2.71 % 40.74 %
Quick Ratio MRQ 19.04 20.86 17.39 40.12 44.58
ELEV's Total Ranking # 213 # 61 # 135 # 16 # 46
Seq. Current Liabilities Change -5.17 % -24.62 % 114.48 % 18.38 % -43.69 %
Seq. Cash & cash equivalent Change -13.44 % -9.59 % -7.02 % 6.53 % 25.2 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 13
Healthcare Sector # 72
Overall Market # 213


Quick Ratio Statistics
High Average Low
44.58 18.42 5.46
(Mar 31 2024)   (Mar 31 2023)




Financial Statements
Elevation Oncology Inc 's Current Liabilities $ 4 Millions Visit ELEV's Balance sheet
Elevation Oncology Inc 's Cash & cash equivalent $ 81 Millions Visit ELEV's Balance sheet
Source of ELEV's Sales Visit ELEV's Sales by Geography


Cumulative Elevation Oncology Inc 's Quick Ratio

ELEV's Quick Ratio for the trailling 12 Months

ELEV Quick Ratio

 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -22.71 % -54.04 % -66.48 % -68.05 % -64.52 %
Y / Y Cash & cash equivalent TTM Growth -0.54 % 14.29 % 9.31 % 3.37 % -1.2 %
Quick Ratio TTM 22.3 26.54 26.44 23.31 17.33
Total Ranking TTM # 2870 # 2229 # 1670 # 879 # 9
Seq. Current Liabilities TTM Growth 12.28 % 2.12 % -9.98 % -25.13 % -33.23 %
Seq. Cash & cash equivalent TTM Growth -5.69 % 2.51 % 2.11 % 0.75 % 8.37 %

Quick ratio ranking by company, industry and sector >> Back to ELEV Financial Strength Comparisons >> Go to Compare ELEV Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2025 to $4.24 millions, cumulative Quick Ratio decreased to 22.3 above the ELEV average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 150 other companies have achieved higher Quick Ratio than Elevation Oncology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2024 from 2229 to 2870.

Explain Quick Ratio?
How much Cash & cash equivalents ELEV´s has?
What are ELEV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 151
Healthcare Sector # 871
Within the Market # 2870


trailing twelve months Quick Ratio Statistics
High Average Low
18.59 10.29 3.28
(Mar 31 2022)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Revolution Medicines Inc   44.26 $ 2,102.675  Millions$ 47.507  Millions
Tourmaline Bio Inc   33.57 $ 249.306  Millions$ 7.426  Millions
Vaxcyte Inc   31.82 $ 1,671.731  Millions$ 52.545  Millions
Cg Oncology Inc   30.41 $ 688.434  Millions$ 22.642  Millions
Engene Therapeutics Inc   28.27 $ 217.392  Millions$ 7.689  Millions
Hillevax Inc   24.38 $ 159.539  Millions$ 6.545  Millions
Tectonic Therapeutic Inc   22.67 $ 306.246  Millions$ 13.510  Millions
Vigil Neuroscience Inc   21.29 $ 87.102  Millions$ 4.091  Millions
Entera Bio Ltd   20.28 $ 12.573  Millions$ 0.620  Millions
Acumen Pharmaceuticals Inc   19.20 $ 149.148  Millions$ 7.767  Millions
Elevation Oncology inc   19.04 $ 80.659  Millions$ 4.236  Millions
Protara Therapeutics Inc  17.72 $ 124.363  Millions$ 7.018  Millions
Inhibikase Therapeutics Inc   17.65 $ 93.180  Millions$ 5.280  Millions
Maze Therapeutics Inc   15.81 $ 294.374  Millions$ 18.617  Millions
Apogee Therapeutics Inc   15.57 $ 513.329  Millions$ 32.960  Millions
Crispr Therapeutics Ag  15.53 $ 1,855.285  Millions$ 119.447  Millions
Qiagen N v   15.12 $ 1,098.918  Millions$ 72.656  Millions
Alpha Cognition Inc.  14.96 $ 45.527  Millions$ 3.044  Millions
Kalaris Therapeutics Inc   14.14 $ 100.965  Millions$ 7.142  Millions
Artiva Biotherapeutics Inc   13.60 $ 165.963  Millions$ 12.204  Millions
Kymera Therapeutics Inc   13.51 $ 463.150  Millions$ 34.273  Millions
Genenta Science S p a   13.29 $ 31.527  Millions$ 2.372  Millions
Imagenebio Inc   12.97 $ 114.051  Millions$ 8.793  Millions
4d Molecular Therapeutics Inc   11.95 $ 321.437  Millions$ 26.899  Millions
Solid Biosciences Inc   11.89 $ 306.918  Millions$ 25.815  Millions
Cullinan Therapeutics Inc   11.68 $ 303.827  Millions$ 26.002  Millions
Century Therapeutics inc   11.39 $ 165.121  Millions$ 14.503  Millions
Scholar Rock Holding Corp  11.36 $ 364.375  Millions$ 32.077  Millions
Aura Biosciences Inc   10.52 $ 127.991  Millions$ 12.163  Millions
Immunovant Inc   10.40 $ 713.971  Millions$ 68.677  Millions

Date modified: 2026-10-05T11:03:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.